ReviewJournal of clinical medicine2022
Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Robot-assisted partial nephrectomy for localized renal masses in elderly and younger patients: a systematic review and meta-analysis of perioperative outcomes.World journal of urology · 2025Pooled it
- Feasibility and Safety of Repeat Robot-Assisted Partial Nephrectomy for Ipsilateral Local Recurrence: A Case Series.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- A bibliometric analysis of the most-cited studies on robotic nephrectomy versus laparoscopic nephrectomy: Citation trends and scientific influence.Investigative and clinical urology · 2026Review
- Evaluating the Efficacy of Robot-Assisted Partial Nephrectomy in Complex Renal Tumours: A Single-Centre Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Clinical outcomes after emergency transarterial renal embolization: a retrospective study.CVIR endovascular · 2024Article
- Outcomes of open versus robotic partial nephrectomy: a 20-year single institution experience.Journal of robotic surgery · 2024Article
- The clinical application value of mixed reality in robotic laparoscopic partial nephrectomy.Frontiers in oncology · 2024Article
- Holographic 3D renal segments reconstruction protects renal function by promote choice of selective renal artery clamping during robot-assisted partial nephrectomy.World journal of urology · 2023Observational
- Long-Term Oncological and Functional Outcomes after Laparoscopic Partial Nephrectomy with Hyperselective Embolization of Tumor Vessels in a Hybrid Operating Room.Journal of clinical medicine · 2023Article
- Clear cell renal cell carcinoma withAmerican journal of clinical and experimental urology · 2023Article
- Off-clamp robotic-assisted partial nephrectomy: surgical experience from a single centre.Central European journal of urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobot-assisted partial nephrectomy (RAPN) is used more and more in present days as a therapy option for surgical treatment of cT1 renal masses. Current guidelines equally recommend open (OPN), laparoscopic (LPN), or robotic partial nephrectomy (PN). The aim of this review was to analyze the most representative RAPN series in terms of reported oncological outcomes. (2) Methods: A systematic search of Webofscience, PUBMED, Clinicaltrials.gov was performed on 1 August 2022. Studies were considered eligible if they: included patients with renal cell carcinoma (RCC) stage T1, were prospective, used randomized clinical trials (RCT) or retrospective studies, had patients undergo RAPN with a minimum follow-up of 48 months. (3) Results: Reported positive surgical margin rates were from 0 to 10.5%. Local recurrence occurred in up to 3.6% of patients. Distant metastases were reported in up to 6.4% of patients. 5-year cancer free survival (CFS) estimates rates ranged from 86.4% to 98.4%. 5-year cancer specific survival (CSS) estimates rates ranged from 90.1% to 100%, and 5-year overall survival (OS) estimates rated ranged from 82.6% to 97.9%. (4) Conclusions: Data coming from retrospective and prospective series shows very good oncologic outcomes after RAPN. Up to now, 10-year survival outcomes were not reported. Taken together, RAPN deliver similar oncologic performance to OPN and LPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.